Considerations for implementing a new combination vaccine into managed care.

Authors: Mullany L,
Address:
Journal: Am J Manag Care.

Publication: 2003 Jan;9(1 Suppl):S23-9.

abstract

BACKGROUND:

The control and elimination of several deadly childhood diseases are a result of extensive vaccination efforts made by pediatricians, family practitioners, public health providers, and health outreach systems. managed care can assist this effort through facilitating the delivery of affordable quality healthcare to patients.

OBJECTIVE:

To describe the Considerations made by managed care when implementing a new vaccine into practice.

RESULTS:

Managed care plans often assess the medical necessity, consumer acceptance, and pharmacoeconomic benefits of a vaccine when considering whether it can be implemented into practice. DTaP-HepB-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine [Combined]), a new combination vaccine, has demonstrated similar immunogenicity and safety when compared with separately administered component vaccines. Use of this combination vaccine will help to simplify the current immunization schedule, and therefore decrease the number of injections infants receive in the first year of life, favorably influencing consumer perception of this new vaccine. A reduction in the number of office visits as a result of fewer injections and improved vaccine compliance may result in a positive pharmacoeconomic impact on parents, physicians, and payers. Reduced administration fees, fewer needed syringes, and decreased risk of needlestick injury resulting from the use of combination vaccines all may have a positive impact on acceptance of these vaccines by managed care organizations.

CONCLUSION:

DTaP-HepB-IPV is expected to meet the tests of medical appropriateness, consumer acceptance, and pharmacoeconomic reasonableness, thereby fulfilling the value proposition of a new combination vaccine for managed healthcare plans.

Related Articles
Benefits of combination vaccines: effective vaccination on a simplified schedule.
Am J Manag Care. 2003
Benefits of combination vaccines: effective vaccination on a simplified schedule.
Dodd D. Am J Manag Care. 2003 Jan; 9(1 Suppl):S6-12.
Review New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Ann Pharmacother. 2010
Review New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL, Hutter GE. Ann Pharmacother. 2010 Mar; 44(3):515-23.
Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.
Pediatr Infect Dis J. 2001
Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.
Yeh SH, Ward JI, Partridge S, Marcy SM, Lee H, Jing J, Curry ES, Howe BJ. Pediatr Infect Dis J. 2001 Oct; 20(10):973-80.
Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
J Pediatr. 2007
Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Cheuvart B, Holmes SJ, 085 Study Investigators. J Pediatr. 2007 Jul; 151(1):43-9, 49.e1-2.
Review New acellular pertussis-containing paediatric combined vaccines.
Vaccine. 1999
Review New acellular pertussis-containing paediatric combined vaccines.
Pines E, Barrand M, Fabre P, Salomon H, Blondeau C, Wood SC, Hoffenbach A. Vaccine. 1999 Mar 26; 17(13-14):1650-6.
Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination.
BMJ. 2003
Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination.
Bellaby P. BMJ. 2003 Sep 27; 327(7417):725-8.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.